For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified ...

A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).

MEDLEMSNYHET - The medical technology group Smith+Nephew uses an AI-supported light microscope ZEISS Axio Imager to inspect ...

MEDLEMSNYHET - SignalChem Biotech (part of Sino Biological) offers integrated solutions to support kinase drug discovery, spanning target discovery to compound screening, profiling, and optimization.

Rådet består sedan innan av ordförande Sven-Eric Söder och ledamöterna Yasmine Bladelius (S), Åsa Gyberg-Karlsson (V), Per ...

Oskar Hansson, a professor of neurology at Lund University, will hold the title of Vice President for Neurodegenerative Disease Early Phase Clinical and Imaging Development at the American ...

Ultimovacs is developing the cancer vaccine UV1, which aims to enhance and improve the effect of immunotherapy in various forms of cancer. Zelluna is developing immunotherapies against solid tumors.

Enligt ett pressmeddelande avgår Hans Wigzell på egen begäran, och styrelsen inleder omedelbart arbetet för att hitta en ny ordförande. Någon orsak anges inte, men beskedet kommer bara en dryg vecka ...

American Merck & Co, known in Europe as MSD, has discontinued the development of vibostolimab and favezelimab, two experimental cancer drugs, after their failure in several trials, according to a ...

– We look for pioneering companies. That's according to Thomas Eldered, chairman of the board of Flerie Invest, who was one of the speakers at Life Science Sweden's Pharma Outsourcing event last week.

The new factory, including a warehouse, will cover 40,000 square meters. Construction has already begun, and the facility is expected to be completed in 2027, according to a press release. – We are ...

Amerikanska Merck & Co, som i Europa är känt som MSD, har beslutat att avbryta utvecklingen av läkemedlen vibostolimab och favezelimab efter flera motgångar, enligt ett pressmeddelande. Dessa ...